EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers

James Cregg iD, Anne V Edwards, Stephanie Chang, Bianca J Lee, John E Knox, Aidan C A Tomlinson, Abby Marquez, Yang Liu, Rebecca Freilich, Naing Aay, Yingyun Wang, Lingyan Jiang und 9 weitere

Journal of Medicinal Chemistry · 27.03.2025 · 68 (6) · 6064-6083

DOI: 10.1021/acs.jmedchem.4c02314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.03.2025. Verfasst von James Cregg und 20 weiteren Autor:innen. Beteiligte Einrichtung: Revolution Medicines, Inc., Redwood City, California 94063, United States. Hauptthemen laut MEDLINE: Antineoplastic Agents, ras Proteins. Die Arbeit wurde bisher 140-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncogenic RAS mutations are among the most common in human cancers. To target the active, GTP-bound state of RAS(ON) directly, we employed an innovative tri-complex inhibitor (TCI) modality. Formation of a complex with an intracellular chaperone protein CypA, an inhibitor, and a target protein RAS blocks effector binding, inhibiting downstream RAS signaling and tumor cell proliferation. Herein, we describe the structure-guided SAR journey that led to the discovery of daraxonrasib (RMC-6236), a noncovalent, potent tri-complex inhibitor of multiple RAS mutant and wild-type (WT) variants. This orally bioavailable bRo5 macrocyclic molecule occupies a unique composite binding pocket comprising CypA and SWI/SWII regions of RAS(ON). To achieve broad-spectrum RAS isoform activity, we deployed an SAR campaign that focused on interactions with residues conserved between mutants and WT RAS isoforms. Concurrent optimization of potency and drug-like properties led to the discovery of daraxonrasib (RMC-6236), currently in clinical evaluation in RAS mutant advanced solid tumors (NCT05379985; NCT06040541; NCT06162221; NCT06445062; NCT06128551).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agentsras ProteinsHumansAnimalsStructure-Activity RelationshipAdministration, OralNeoplasmsCell Line, TumorDrug DiscoveryMiceBiological AvailabilityRatsCell Proliferation

Substanzen

Antineoplastic Agentsras Proteins

Autor:innen und Institutionen

  • Revolution Medicines, Inc., Redwood City, California 94063, United States.

ORCID-Profile: James Cregg, Elena S Koltun

Zitieren

APA

Cregg, J., Edwards, A. V., Chang, S., Lee, B. J., Knox, J. E., Tomlinson, A. C. A., Marquez, A., Liu, Y., Freilich, R., Aay, N., Wang, Y., Jiang, L., Jiang, J., Wang, Z., Flagella, M., Wildes, D., Smith, J. A. M., Singh, M., Wang, Z., …, & Koltun, E. S. (2025). Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. Journal of Medicinal Chemistry, 68(6), 6064-6083. https://doi.org/10.1021/acs.jmedchem.4c02314

Vancouver

Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, et al. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. Journal of Medicinal Chemistry. 2025;68(6):6064-6083. doi:10.1021/acs.jmedchem.4c02314

BibTeX
@article{Cregg2025,
  author = {Cregg, James and Edwards, Anne V and Chang, Stephanie and Lee, Bianca J and Knox, John E and Tomlinson, Aidan C A and Marquez, Abby and Liu, Yang and Freilich, Rebecca and Aay, Naing and Wang, Yingyun and Jiang, Lingyan and Jiang, Jingjing and Wang, Zhican and Flagella, Michael and Wildes, David and Smith, Jacqueline A M and Singh, Mallika and Wang, Zhengping and Gill, Adrian L and Koltun, Elena S},
  title = {Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {6},
  pages = {6064--6083},
  doi = {10.1021/acs.jmedchem.4c02314}
}
Kostenlos starten →